Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver

Colorectal Adenocarcinoma Metastatic to the Liver Clinical Trial

Official title:

A Randomized, Multicenter Phase II Study of Panitumumab Plus FOLFIRI With or Without Hepatic Arterial Infusion as Second-Line Treatment in Patients With Wild Type RAS Who Have Unresectable Hepatic Metastases From Colorectal Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03069950
• Other study ID #: 16-1341
• Status: Withdrawn
• Phase: Phase 2
• Start date: February 28, 2017
• Est. completion date: May 16, 2019

Study information

• Verified date: May 2019
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see if patients treated with both regional chemotherapy using the HAI pump and intravenous chemotherapy are able to have their liver tumors removed surgically (resected), versus treatment with only intravenous chemotherapy.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 16, 2019
• Est. primary completion date: May 16, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed by the enrolling institution.

• Patients must have a primary L sided colorectal cancer, (at or distal to the splenic flexure)

• Confirmed RAS/RAF wild type tumor. Paraffin-embedded tumor tissue obtained from the primary tumor or metastasis

• Have received prior treatment for metastatic disease with oxaliplatin-based regimen and either

• Had disease progression OR

• Had stable disease OR

• Discontinued oxaliplatin due to neuropathy

• Patients must meet the following criteria for unresectability as determined by two hepatobiliary surgeons and one radiologist:

• When a margin negative resection would require resection of all three hepatic veins, both portal veins, or the retrohepatic vena cava.

• Requiring a resection that leaves less than 2 hepatic segments (not including the caudate lobe) behind with adequate arterial/portal inflow, venous outflow and biliary drainage. **

**A patient is considered resectable if the procedure includes a minor wedge or thermo-ablation encompassing 10% or less of the volume of the remaining 2 segments.

• Patient?s liver metastases must comprise <70% of the liver parenchyma. All patients must be clinically fit to undergo surgery as determined by the pre-operative evaluation

• Lab values within 14 days prior to enrollment/randomization:

• WBC = 3.0 K/uL

• ANC > 1.5 K/uL

• Platelets = 100,000/uL

• Renal function (= 10 days prior to enrollment/randomization) °Creatinine = 1.5 mg/dL or creatinine clearance = 50 mL/min calculated by the Cockcroft-Gault method as follows:

Cockcroft-Gault method as follows:

• Male creatinine clearance = (140 -age in years) x (weight in Kg) / (serum Cr in mg/dl x 72)

• Female creatinine clearance = (140 - age in years) x (weight in Kg) x 0.85 / (serum Cr in mg/dl x 72) (use of creatinine clearance per protocol based on chemotherapy regimen)

• Hepatic function, as follows: (= 10 days prior to enrollment/randomization)

• Total Bilirubin = 1.5 mg/dl

• Calcium = lower limit of normal (= 48 hours prior to enrollment/randomization)

• KPS = 60% (ECOG (or Karnofsky) performance status (preferably 0 or 1/= 60% for Karnofsky))

Exclusion Criteria:

• Patients < 18 years of age

• Patients who have received more than one chemotherapy regimen for metastatic disease

• Patients who are chemotherapy naïve

• Prior radiation to the liver (Prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration)

• Active infection

°Active infection includes patients with positive blood cultures

• Prior treatment with HAI FUDR

• Prior TACE

• Female patients who are pregnant or lactating - or planning to become pregnant within 6 months after the end of the treatment (female patients of child-bearing potential must have negative pregnancy test = 72 hours before enrollment and randomization, and must have a negative pregnancy test = 72 hours prior to treatment start)

• If a patient has any serious medical problems which may preclude receiving this type of treatment

• Patients with history or known presence of primary CNS tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded.

• Serious or non-healing active wound, ulcer, or bone fracture

• History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan

• Patients who have a diagnosis of Gilbert?s disease

• History of other malignancy, except:

1. Malignancy treated with curative intent and with no known active disease present for = 3 years prior to randomization and felt to be at low risk for recurrence by the treating physician

2. Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease

3. Adequately treated cervical carcinoma in situ without evidence of disease

Related Conditions & MeSH terms

• Adenocarcinoma
• Colorectal Adenocarcinoma Metastatic to the Liver
• Colorectal Neoplasms

Intervention

Drug:
• Floxuridine (FUDR)
5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
• Irinotecan (CPT-11)
Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
• FLUOROURACIL
5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
• PANITUMUMAB
Panitumumab (6 mg/kg IV over 60 min)
• DEXAMETHASONE
flat dose of 25 mg on Day 1
• Leucovorin
Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Basking Ridge	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Commack	Commack	New York
United States	Memoral Sloan Kettering Westchester	Harrison	New York
United States	Memorial Sloan Kettering Monmouth	Middletown	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (5)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Oregon Health and Science University, Queens Cancer Center of Queens Hospital, The Cleveland Clinic, Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resection rate assessed using RECIST (version 1.1)	Treatment evaluation will be done using RECIST (version 1.1) The patient will be assessed with repeat CT scans as specified. If at any time after 3 cycles (or 3 months) the patient is able to undergo a complete resection of all hepatic metastases they will proceed to operative assessment.	3 months

External Links

•   Memorial Sloan Kettering Cancer Center